Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer  

作　　者：Mattias Carlsten Yenan T.Bryceson 

机构地区：[1]Center for Hematology and Regenerative Medicine,Department of Medicine Huddinge,Karolinska Institute,14157 Stockholm,Sweden [2]Center for Cell Therapy and Allogeneic Stem Cell Transplantation,Karolinska Comprehensive Cancer Center,Karolinska University Hospital,17176 Stockholm,Sweden [3]Division of Clinical Immunology and Transfusion Medicine,Karolinska University Hospital,17176 Stockholm,Sweden [4]Broegelmann Research Laboratory,Department of Clinical Sciences,University of Bergen,5030 Bergen,Norway

出　　处：《Signal Transduction and Targeted Therapy》2023年第9期3892-3893,共2页信号转导与靶向治疗（英文）

基　　金：This work was supported by grants from the Swedish Cancer Foundation and Swedish Research Council(to M.C.and Y.T.B.);the Knut and Alice Wallenberg Fellows program(to Y.T.B.).

摘　　要：In a recent study published in Nature Immunology,Zheng et al.discovered that intratumoral NK cells were smooth and rounded as opposed to the typical vili-rich,rougher surface of normal NK cells.1 This phenotype was linked to a specific deficit in membrane sphingomyelin lipids that impaired tumor cell killing.Importantly,results suggested that NK cell-mediated immunosurveillance of cancer can be rescued by blocking enzymes that degrade sphingomyelin,uncovering a potential novel‘metabolic immune checkpoint’for which pharmacological inhibition holds promise for cancer therapy.NK cells are generally considered a subset of innate lymphoid cells that mediate cellular cytotoxicity.

关 键 词：MYELIN IMPAIRED CANCER 

分 类 号：R730.5[医药卫生—肿瘤]